{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-018687","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.097287+00:00","generated_at":"2026-06-25T22:40:44.320496+00:00","sec_items":["5.03","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TherapeuticsMD effects 1-for-50 reverse stock split; authorized shares cut to 12M","bullets":["Reverse split effective May 6, 2022; every 50 shares become 1 share.","Authorized shares reduced from 600M to 12M; fractional shares rounded up.","Trading on split-adjusted basis under TXMD begins May 9, 2022.","No stockholder approval required under Nevada law."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-018687","json":"https://secwatch.observer/filing/0001564590-22-018687.json","markdown":"https://secwatch.observer/filing/0001564590-22-018687.md","text":"https://secwatch.observer/filing/0001564590-22-018687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000156459022018687/0001564590-22-018687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000156459022018687/txmd-8k_20220503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:40:44.320496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}